CDC's Opioid Final Guideline Narrows Duration Of Use For Chronic Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Three days of opioid use for acute pain 'will often be sufficient' and more than seven days 'will rarely be needed;' NEJM editorial by CDC officials emphasizes risks of opioid use.
You may also be interested in...
Opana ER Panel Urged To Disregard ‘Invalid’ Human Abuse Liability Study
In unusual public hearing, Edwin Thompson, head of the US firm that contract manufactures Endo’s long-acting opioid, tells US FDA advisory committee that intranasal ‘liking’ study violated FDA requirements. Thompson has petitioned the agency to do away with need for human abuse liability studies entirely, asserting they are inherently flawed.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.